BridgeBio Pharma, Inc. 4

BridgeBio Pharma President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld for taxes related to RSU vesting, leaving him with 336,529 shares owned.

On August 16, 2026, BridgeBio Pharma, Inc. President and CFO Thomas Trimarchi had 22,781 shares of common stock withheld by the company at an implied price of $79.86 per share to satisfy tax obligations arising from the vesting of 41,194 RSU-based common shares; this is a routine administrative withholding rather than an open-market trade. Following the tax withholding, Trimarchi beneficially owned 336,529 shares of BridgeBio common stock, which at the same $79.86 reference price represents an equity stake worth approximately $26.9 million. The Form 4 footnote also notes a separate acquisition of 116 shares on August 14, 2026 through the issuer's Employee Stock Purchase Plan, which was exempt from Section 16(b) and not the primary subject of the reported transaction.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

4

Source Type

fda

Accession

0001470831-26-000837

Alert Tier

5